Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Featured Resources

A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics

On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient
Watch Now

Accelerate Protein Screening by Sequencing Protein Barcodes on Platinum®

On-demand webinar presented by Joel McDade, PhD, Sr. Commercial Business Development Manager, Quantum-Si and Bonnie Lun, PhD, Field Application Scientist
Watch Now

Challenges and Strategies for the Application of Omics and Spatial Technologies

A concise report featuring insights from the prominent thought leaders of Omics 2023 and Spatial 2024
Read Now

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now

Introducing: LifeScienceXchange

Patients are counting on your R&D community for the next wave of life-saving medicines.

LifeScienceXchange is the catalyst: a platform for leaders from diverse life science disciplines to connect, learn and collaborate, so that together we bring new treatments to patients faster, sustainably and at scale.

Providing actionable market insights, technology showcases, thought leadership and essential news, all in a condensed and curated video format.

It will help you understand trends, benchmark your work, inform strategy and ultimately get your new treatments to patients, faster.

Precision Medicine on LifeScienceXchange provides the events and channels for R&D to unlock human data for precise, patient-centric solutions.

LSX Logo - Better Patient Slogan

Learn faster and put new ideas to work

Market Insights unlock key learnings and actionable ideas from our industry-leading live events. We’ve cut and curated more than 6,000 hours of live recordings into quick-watch cuts, so you can get straight to the moments that matter.

Innovate sooner and benchmark success

Our Technology Showcases give you first sight of the breakthroughs driving our industry. We put you in touch with new developments and vendor success stories, so you can understand the tech, connect with the innovators and benchmark your work against the best

Learn and share ideas with industry leaders

Our Thought Leadership opportunities put you at the heart of the conversations accelerating life sciences R&D today. Hear interviews and presentations with key opinion leaders each month — and join the conversation by putting your questions to them live.

Get the full picture faster

Our Weekly News digest clarifies and condenses the key developments and talking points in life sciences R&D. Each week we identify and summarise the five top stories in quick-read format, so you have a full, clear and balanced picture.

Clinical Development

Surrogate Biomarkers in NASH and Liver Cirrhosis: Qualifying for Clinical Trial Validation and Legislative Success

Highly involved treatment scenarios and prognostics are required to properly assess best-practice approaches for investigating issues posed by NASH and liver cirrhosis. Surrogate biomarkers present a less invasive approach to assessing these outcomes.
Read More
Diagnostic Development

Emergency Use Authorization Issued by FDA for Mpox Virus DNA Test

EUAs exist under FDA regulation to improve the availability of medical countermeasures, such as vaccines and diagnostic tests, during public health emergencies. With future pandemics a tangible possibility, further EUAs for other PCR tests and vaccines are all but certain.
Read More
Genomic Biomarkers

Clinical Biomarker Trends to Watch in 2023

The identification of novel clinical biomarkers is set to continue, with further research and investment in fields such as next-gen sequencing and miRNA targeting.
Read More
Genome Editing

Policy Issues for Responsible Genomics Research

Responsible genomics research is vital to ensuring the advancement of health for society. But what are the ethical, social, and legal considerations that go into genomics-based decision making?
Read More
Clinical Development

Keytruda sees Trial Success in Treating Endometrial Cancer Patients

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.
Read More
Clinical Development

Eli Lilly Focus on Phase III Trial for Alzheimer’s Treatment Following FDA Fast Lane Setback

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.
Read More
Clinical Diagnostics

Long-Read Sequencing Named 'Method of the Year 2022'

Powering a more complete reading of genomic information, Nature hails long-read sequencing as the omics-based method of the year.
Read More
Clinical Development

FDA Approves Merck-Developed KEYTRUDA for Non-Small Cell Lung Cancer Therapy

KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival in patients following surgical resection and platinum-based chemotherapy.
Read More
Spatial Analysis

The Future of Spatial Technology, Analysis, and Imaging

This Insight Article looks at the short and long-term predictions for spatial technological regulation, standardisation, and collaboration for the omics field.
Read More
Biomarker Discovery & Development

Bioassay Optimisation: How the Pandemic Reshaped International Standards for New Therapeutics

The global race to develop, trial, and distribute a vaccine for Covid-19 may have permanently accelerated the development of future therapeutics, including treatments for cancer.
Read More
Clinical Diagnostics

FDA Clears Genomic Profiling Test for Solid Tumours 

Regulatory approval for comprehensive genomic profiling test signifies “significant advancement in personalised cancer care.”
Read More
Genome Editing

FDA and NIH Sign Interagency Collaboration Agreement to Advance Proteogenomics Research

A memorandum of understanding has been reached between the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to provide a framework for solving complex problems in molecular characterisation and classification of tumours.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things discovery